Salts of benzimidazole compound and use thereof

Abstract

A sodium salt, magnesium salt, lithium salt, potassium salt, calcium salt or barium salt of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, and a pharmaceutical composition comprising the salt. The novel salt is useful as an excellent antiulcer agent.

1 - 13 . (canceled)  
   
   
       14 . A method for preventing or treating gastritis, reflux esophagitis, NUD (Non-Ulcer Dyspepsia), gastric cancer, gastricMALT lymphoma, upper gastrointestinal hemorrhage or hyperacidity, which comprises administering an effective amount of at least one selected from the group consisting of a crystalline sodium salt, a crystalline lithium salt, a crystalline potassium salt, a crystalline magnesium salt, a crystalline calcium salt and a crystalline barium salt of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole to a human in need thereof.  
   
   
       15 . A method for eradicating  Helicobacter pylori , which comprises administering an effective amount of at least one selected from the group consisting of a crystalline sodium salt, a crystalline lithium salt, a crystalline potassium salt, a crystalline magnesium salt, a crystalline calcium salt or a crystalline barium salt of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole to a human in need thereof.  
   
   
       16 . The method according to  claim 14 , wherein said salt is a solvate with water or an alcohol, or a non-solvate.  
   
   
       17 . The method according to  claim 14 , wherein said salt is a crystalline sodium salt of (R)-2-[[[3-methyl4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole.  
   
   
       18 . The method according to  claim 17 , wherein the crystalline sodium salt has an X-ray diffraction spectrum with the following diffraction peaks: 
 (i) 15.02, 7.53, 7.05, 5.53, 4.17, 3.96, 3.42, 3.33 Å,    (ii) 16.00, 12,65, 7.98, 7.51, 6.35, 5.09, 4.99, 4.92, 4.82, 4.21 Å, or    (iii) 8.89, 8.47, 5.64, 5.24, 4.84, 4.23, 4.20, 4.09, 3.60, 3.36 Å.    
   
   
       19 . The method according to  claim 14 , wherein said salt is a crystalline potassium salt of (R)-2-[[[3-methyl4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole.  
   
   
       20 . The method according to  claim 19 , wherein the potassium has an X-ray diffraction spectrum with the following diffraction peaks: 
 (i) 16.35, 8.17, 6.81, 5.78, 4.93, 4.50, 4.25, 4.08, 3.65, 3.36, 3.02 Å.    
   
   
       21 . The method according to  claim 15 , wherein said salt is a solvate with water or an alcohol, or a non-solvate.  
   
   
       22 . The method according to  claim 15 , wherein said salt is a crystalline sodium salt of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole.  
   
   
       23 . The method according to  claim 15 , wherein said salt is a crystalline potassium salt of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole.